AtheroGenics Announces Change in Chief Medical Officer
G. Alexander Fleming, M.D. Appointed Acting Chief Medical Officer
October 18, 2007: 09:30 AM EST
AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced the resignation of Rob Scott, M.D., Executive Vice President of Research & Development and Chief Medical Officer, to pursue other interests. Effective immediately, G. Alexander Fleming, M.D., will fill the post as Acting Chief Medical Officer. Dr. Fleming is President and Chief Executive Officer of Kinexum LLC, a prominent life sciences consulting firm, and is a former senior physician at the U.S. Food and Drug Administration and a recognized expert in diabetes therapeutic development.
"We are very much looking forward to working with Zan Fleming as he assumes this key role at AtheroGenics. We believe that his extensive and highly relevant industry experience in the diabetes therapeutic area will prove invaluable to our Company and, in particular, to our on-going Phase III ANDES trial of AGI-1067 in diabetes," stated Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer of AtheroGenics. "All of us would like to thank Rob for his contributions to the Company during the past several years, and we wish him success in his future endeavors."
"Having reviewed its very large clinical database, I believe AGI-1067 has great potential to be an important treatment for diabetes," commented Dr. Fleming. "I am excited to have this opportunity to help bring it through Phase III and to patients for whom there is an acute unmet medical need in this disease area."
Dr. Fleming served twelve years as FDA Supervisory Medical Officer for diabetes and other metabolic and endocrine disorders and had assignments with the World Health Organization (WHO) and the International Conference on Harmonization (ICH). At FDA, he led reviews and was responsible for the regulation of a number of diabetes and other metabolic therapies, including insulin analogs and metformin. He brings extensive industry experience as chief medical and scientific officer and board member.<snip> |
